Another "predator" into the market, 3 billion injections of large varieties of the market or change

"Pharmaceutical Network Market Analysis" After Shijiazhuang four drugs hydrochloric acid right metomidin injection to copy the class 3 submitted to the listing application was accepted by CDErecently, Jiangsu Zhengda Qingjiang Pharmaceutical hydrochloric acid right-mememieding injection also with imitation 3 categories of listingdata show that the species is a relatively selective alpha2-epinephrine antagonist, suitable for general anaesthetic surgery patients trachea intubation and mechanical ventilation sedationoriginal research products developed by Orion and Abbott, was approved in the United States in 1999, the product is called ex, has been in the United States, Japan, China, the European Union and other countries and regions listed for saleaccording to data from- and inner-,net, sales of injectable injections at the ends of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as public medical institutions in China) reached 3.599 billion yuan in 2019at present, the domestic production enterprises have Hengrui Pharmaceuticals, Yangzijiang Pharmaceuticals, Chen Xin Pharmaceuticals, Enhua Pharmaceuticals, Hunan Collun Pharmaceuticals and other 10consistency evaluation, only Yangzijiang Pharmaceuticals has a reviewon the 2019 China public medical institutions terminal right-hand Metomi fixed injection brand pattern, Hengrui Pharmaceuticals accounted for 53.21 percent of the market share, followed by Yangzijiang Pharmaceuticals, the market share of 32.94 percentEnhua Pharmaceuticals, Guorui Pharmaceuticals, Chenxin Pharmaceuticals and other enterprises have a market share of less than 7%, accounting for a small proportionit is worth mentioning that the market share of Yangzijiang Pharmaceutical sourcing products has been expanding in recent yearsJune 2018, Yangzijiang Pharmaceuticals' hydrochloric acid right-metomidin injection was approved for sale as a class of 3 imitations and reviewedthen the variety won the bid "4 plus 7" collection, the alliance region, market share has been rapid growth, from 2018 to 2019, from less than 1% to more than 180 times, market share exceeded 30%, second only to Hengrui Pharmaceuticalsbut Hengrui Pharmaceuticals is also expanding its sales in the marketrecently announced that the company recently received the FDA notice, declared the hydrochloric acid right metomiedinized sodium chloride injection of a simplified new drug application has been approvedapproval marks HengRui Pharma's qualifications to market the drug in the U.Smarket and will have a positive impact on the company's market expansionsaid it would actively promote the drug's marketthe 3 billion injections of Jiangsu Zhengda Qingjiang Pharmaceutical, according to public information, the company is a joint venture between Zhengda Pharmaceutical Group and Jiangsu Agricultural Reclamation Group to form a foreign-funded enterprisescompany's main Chinese and Western pharmaceutical preparations and chemical synthetic raw materials, with solid preparations, Chinese medicine extraction, chemical synthetic raw materials and other production workshop, there are Chinese and Western pharmaceutical tablets, capsules, pills, cephalosporines, anti-tumor raw materials and preparations and other GMP production linescompany in Nanjing and Huai'an have product research and development centers, each year 4-5 new products on the marketindustry analysts believe that in these competitions behind a series of "actions", the market for psychostabilising drugs or will be another storm-meter-net data show that in 2019, China's public medical institutions terminal chemical psychostabilizer sales exceeded 15 billion yuan, an increase of 9.64 percent year-on-yearas of June 23, 15 products of psychostable drugs through (including the adoption of the same) consistency evaluation, of which, the right zopigron tablet, chlor-nitrogen flat tablet, fumatox-pyridine sulfur-relief tablets and other 6 products have 3 or more enterprises have been ratedand from the dosage form, the injection only hydrochloric acid right metomiedin injection 1 over rated